Study guide

Uveal melanoma and retinoblastoma

European Board of Ophthalmology Diploma EBOD

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: EBOD Examination, Applications and Regulations

EBOD Format, Scoring and Revision Planning Eligibility, Applications and the Diploma Online Rules, Technical Preparation and Appeals

2 Chapter 2: Physical Optics, Photometry and Lenses

Light, refraction and total internal reflection Photometry, contrast, colour and adaptation Prisms, decentration and vector combination Vergence, astigmatic lenses and Sturm’s conoid

3 Chapter 3: Instrument Optics, Aberrations and Laser Physics

Cross-cylinder and diagnostic instrument optics Aberrations, duochrome and wavefront analysis Diffraction, polarization, lasers and OCT

4 Chapter 4: Refraction, Accommodation and Spectacle Prescribing

Objective and cycloplegic refraction Subjective refraction and binocular balance Accommodation, presbyopia and vertex distance Spectacle Materials, Measurement and Progressive Lenses

5 Chapter 5: Contact Lenses and Low-Vision Rehabilitation

Contact-lens optics, materials and tear lenses Contact-lens fit and complications Low-vision assessment and magnification Low-vision aids, calculations and ergonomics

6 Chapter 6: Extraocular Anatomy and Motor Physiology

Extraocular muscle anatomy and innervation Eye axes, kinematics and muscle actions Motor laws and orbital pulleys

7 Chapter 7: Binocular Vision and Amblyopia

Binocular vision, stereopsis and the horopter Suppression, correspondence and microtropia Sensory tests and amblyopia treatment

8 Chapter 8: Childhood Assessment and Strabismus Testing

Visual Development, Childhood Testing and Developmental Delay History, corneal reflexes and cover tests Motility patterns, three-step testing and Hess charts

9 Chapter 9: Esotropia, Exotropia and Vertical Deviations

Infantile and accommodative esotropia Exotropia classification and management Vertical Deviations, A–V Patterns and Skew

10 Chapter 10: Dysinnervation, Nystagmus and Muscle Surgery

Duane syndrome, Brown syndrome and restriction Nystagmus patterns and investigation Nystagmus and muscle surgery principles

11 Chapter 11: ROP and Paediatric Ocular Disease

Retinopathy of Prematurity: Screening, Classification and Follow-up Childhood Cataract, Leukocoria and Congenital Glaucoma Childhood Systemic Disease, Infection and Safeguarding

12 Chapter 12: Ocular Surface Anatomy and Infection

Corneal, Conjunctival and Scleral Structure: Examination and Sampling Bacterial keratitis, sampling and treatment Fungal, amoebic and herpetic keratitis Infectious, chlamydial and neonatal conjunctivitis

13 Chapter 13: Allergy, Cicatrisation and Surface Inflammation

Allergic eye disease, trachoma and phlyctenules Cicatrising Conjunctivitis: Mucous Membrane Pemphigoid and SJS/TEN Dry eye, blepharitis and meibomian dysfunction PUK, interstitial keratitis and scleritis

14 Chapter 14: Anterior Segment Dysgenesis and Corneal Dystrophies

Anterior Segment Dysgenesis, Aniridia and Congenital Corneal Opacity IC3D and epithelial or Bowman-layer dystrophies Stromal corneal dystrophies Endothelial corneal dystrophies

15 Chapter 15: Corneal Degeneration, Ectasia and Epithelial Failure

Corneal Degenerations, Pterygium, Band Keratopathy and Dellen Keratoconus and clinical ectasia signs Ectasia imaging, cross-linking and rehabilitation Recurrent Erosion, Neurotrophic Keratopathy and Vitamin A Deficiency

16 Chapter 16: Surface Reconstruction and Keratoplasty

Limbal Stem-Cell Failure, Tarsorrhaphy and Phototherapeutic Keratectomy PK, DALK and endothelial keratoplasty Corneal graft immunity and rejection recognition Graft rejection treatment and postoperative problems

17 Chapter 17: Lens Development, Cataract Assessment and Biometry

Lens Development, Congenital Shape and Ectopia Lentis Lens anatomy and age-related cataract phenotypes Cataract grading, secondary causes and childhood disease Optical and ultrasound biometry

18 Chapter 18: IOL Planning and Phacoemulsification

Keratometry and IOL power formulae Post-refractive biometry, toric alignment and IOL design Phaco fluidics and ultrasound delivery Wounds, OVDs and nucleus techniques

19 Chapter 19: Cataract Anaesthesia and Surgical Complications

Cataract Anaesthesia, Alternative Extraction and Combined Procedures IFIS, capsule rupture and compromised support Postoperative inflammation, haemorrhage and PCO

20 Chapter 20: Corneal and Intraocular Refractive Surgery

Excimer ablation, PRK and LASIK SMILE, surgical selection and complications Phakic IOLs and refractive lens exchange

21 Chapter 21: Presbyopia Procedures and Surface Therapeutics

Presbyopia Surgery, Monovision and Historical Refractive Procedures Surface antimicrobial and anti-inflammatory pharmacology Surface healing, amnion and cenegermin

22 Chapter 22: Aqueous Dynamics, Tonometry and Gonioscopy

Ciliary body and aqueous secretion Outflow and the Goldmann pressure model Tonometry, corneal thickness and biomechanics Gonioscopy optics, landmarks and indentation

23 Chapter 23: Angle, Disc and Visual-Field Assessment

Angle grading and anterior-segment imaging Optic-disc examination and documentation OCT and automated perimetry

24 Chapter 24: Glaucoma Progression, Suspects and Secondary Mechanisms

Field reliability and progression Ocular hypertension, suspects and juvenile glaucoma Lens-related glaucoma, aqueous misdirection and venous pressure

25 Chapter 25: POAG, Angle Closure and Pigmentary Disease

POAG, target pressure and normal-tension disease Angle-closure classification and mechanisms Acute angle closure, iridotomy and lens extraction Pseudoexfoliation and pigmentary glaucoma

26 Chapter 26: Glaucoma Medical, Laser and Surgical Treatment

Neovascular, uveitic and steroid-response glaucoma Glaucoma medicines, SLT and MIGS Trabeculectomy and drainage implants Nonpenetrating surgery, cyclodestruction and postoperative lasers

27 Chapter 27: Retinal Imaging, Diabetes and Vascular Occlusion

Retinal anatomy, examination and multimodal imaging Diabetic microangiopathy and NPDR classification PDR, macular oedema and diabetic trials Retinal vein and artery occlusions

28 Chapter 28: Uncommon Vascular Disease and Myopic Maculopathy

Macroaneurysm, sickle retinopathy and retinal periphlebitis Coats disease and leukocoria assessment MacTel and radiation retinopathy Myopic maculopathy and presumed ocular histoplasmosis

29 Chapter 29: Inherited Retina and Electrophysiology

Retinitis pigmentosa and inherited degeneration Stargardt, Best disease and retinal electrophysiology Cone disorders, stationary night blindness and syndromic retina

30 Chapter 30: AMD, Geographic Atrophy and Pachychoroid

AMD biology and clinical staging Drusen, geographic atrophy and neovascular phenotypes Neovascular AMD trials and treatment CSCR and the pachychoroid spectrum

31 Chapter 31: Retinal Breaks and Detachment Repair

PVD, peripheral degenerations and retinal breaks RRD localization and retinoschisis Detachment mechanisms, pneumatic retinopexy and scleral buckling

32 Chapter 32: Vitrectomy, Macular Surgery and Retinal Trauma

Vitrectomy and intraocular tamponades ERM, macular holes and PVR Retinal trauma, optic-disc pits and choroidal detachment

33 Chapter 33: Uveitis Classification and Non-Infectious Inflammation

SUN classification, grading and uveitis work-up Anterior and intermediate uveitis patterns HLA-B27, sarcoidosis, Behçet disease and VKH Posterior inflammatory patterns and immunomodulation

34 Chapter 34: Infectious Uveitis and Endophthalmitis

Toxoplasmosis and herpetic necrotizing retinitis Ocular syphilis and tuberculosis Immunosuppressed retinitis, toxocariasis and neuroretinitis Endophthalmitis diagnosis and treatment

35 Chapter 35: Optic Neuritis and Ischaemic Optic Neuropathy

Typical optic neuritis and ONTT NMOSD and MOGAD Arteritic optic neuropathy and GCA NAION and ischaemic neuropathy comparison

36 Chapter 36: Papilloedema, IIH and Afferent Localisation

Papilloedema recognition and Frisén grading IIH diagnosis and vision protection Disc drusen and pseudopapilloedema Afferent pathways and chiasmal localization

37 Chapter 37: Congenital, Inherited and Cortical Neuro-Ophthalmology

Cortical vision and higher visual syndromes Neuro-ophthalmic testing and congenital optic discs Inherited, compressive, infiltrative and nutritional optic neuropathies Transient visual loss, headache and neurological emergencies

38 Chapter 38: Central Motor Control and Cranial Nerve Palsies

Central ocular motor control and supranuclear disorders Third- and fourth-nerve palsies Sixth nerve, pontine gaze and cavernous sinus

39 Chapter 39: Myasthenia and Ocular Myopathy

Myasthenic ocular weakness Myasthenia testing and treatment Myopathy, CPEO and Kearns–Sayre syndrome

40 Chapter 40: Pupillary Pathways and Anisocoria

Pupillary pathways and afferent defects Horner syndrome and tonic pupil Light–near dissociation and pupil differentials

41 Chapter 41: Orbit, Thyroid Eye Disease and Ptosis Assessment

Orbital anatomy and thyroid eye disease Orbital infection and idiopathic inflammation Orbital masses, approaches and eye-removal procedures Lid anatomy and ptosis evaluation

42 Chapter 42: Lid Repair and Lacrimal Drainage

Ptosis repair, malposition and eyelid tumours Lash disorders, facial palsy and lid reconstruction Lacrimal drainage and epiphora testing Nasolacrimal obstruction, infection and DCR

43 Chapter 43: Lacrimal Gland Disease, Pathology and Intraocular Tumours

Lacrimal gland inflammation and tumours Ocular histology, specimen handling and special stains Immunophenotyping, molecular pathology and tumour genetics Uveal melanoma and retinoblastoma

44 Chapter 44: Lymphoma, Surface Tumours and Paraneoplastic Disease

Vitreoretinal lymphoma Surface tumours, uveal metastases and benign mimics Paraneoplastic retinopathy, treatment effects and counselling

45 Chapter 45: Ocular Trauma and Vascular Systemic Disease

Trauma terminology and prognostic scoring Chemical injury and surface preservation Open-globe emergency management Vascular, endocrine, pregnancy and renal eye disease

46 Chapter 46: Multisystem Disease and Ophthalmic Pharmacology

Immune, metabolic and multisystem ocular clues Phakomatoses and syndrome-specific surveillance Connective-tissue and metabolic ocular disease Drug delivery and systemic glaucoma effects

47 Chapter 47: Medication Toxicity, Professional Practice and Clinical Stations

Retinal and optic medication toxicity Prevention, consent and professional practice Directed clinical answers and station rehearsal

Uveal melanoma and retinoblastoma

Key Takeaways Explain This Topic AI

COMS found similar survival in its medium-melanoma treatment comparison but does not define every modern treatment decision.

Retinoblastoma genetics require constitutional assessment and counselling rather than assumptions from family history alone.

Suspected retinoblastoma needs specialist management that avoids casual intraocular biopsy and seeding risk.

Last updated: October 2026

Uveal Melanoma: Epidemiology & Clinical Features

Uveal melanoma represents the most common primary intraocular malignancy in adults, with an annual incidence in European populations of approximately 5 to 7 cases per million . Arising from neuroectodermal melanocytes within the uveal tract, its anatomical distribution is:

Choroid (85-90%): Most frequent site.

Ciliary Body (5-8%): Diagnosed later due to hidden location behind the iris; associated with poorer prognosis.

Iris (3-5%): Diagnosed earliest; carries the most favorable prognosis.

Risk Stratification: Choroidal Nevus versus Melanoma

The contemporary imaging mnemonic TFSOM-DIM highlights thickness over 2 mm on ultrasound, subretinal fluid on OCT, symptoms with acuity 20/50 or worse, orange pigment on autofluorescence, melanoma acoustic hollowness and diameter over 5 mm on photography. These risk features help referral and surveillance; they are not a histological diagnosis or the same as older clinical mnemonics. Compare serial size, fluid and symptoms, and seek ocular-oncology assessment when suspicious.

Multimodal Ophthalmic Imaging Hallmarks

B-Scan Ultrasonography:

Tumour Shape: Typically dome-shaped in early stages. Rupture of the tumor through Bruch's membrane produces the characteristic collar-button (mushroom) configuration with a narrow neck and expanded apical head.

Acoustic Hollowness: The dense, homogeneous cellular composition of melanoma causes progressive acoustic attenuation, manifesting as internal acoustic hollowness (hyporeflective tumor parenchyma).

Choroidal Excavation: Apparent backward bowing or indentation of the underlying scleral contour due to replacement of the normal highly reflective choroid by hyporeflective tumor tissue.

A-Scan Ultrasonography:

Demonstrates a high initial surface spike followed by low-to-medium regular internal reflectivity (characteristically < 40 − 60 % <40-60\% < 40 − 60% , usually 10 − 40 % 10-40\% 10 − 40% ) with a distinctive declining acoustic gradient ( "kappa angle" ), reflecting acoustic absorption.

Optical Coherence Tomography (OCT):

Visualizes subretinal fluid, elongated "shaggy" photoreceptor outer segments, and intraretinal cystoid spaces.

Fluorescein Angiography (FFA):

In collar-button tumors, reveals the "double circulation" pattern : simultaneous visualization of the superficial retinal capillary network and the deeper, intrinsic tumor vasculature.

Landmark COMS Trial Findings & Genetic Prognostication

The multicentre Collaborative Ocular Melanoma Study (COMS) established modern treatment paradigms:

COMS eligibility : The medium-tumour trial included height 2.5–10 mm (up to 8 mm near the disc) and largest basal diameter no more than 16 mm. Use the actual trial eligibility rather than a fabricated universal size table.

The Medium Tumour Trial (Brachytherapy vs. Enucleation):

Randomized patients with medium-sized choroidal melanoma to either Iodine-125 ( 125 I ^{125}\text{I} 125 I ) plaque brachytherapy or primary enucleation .

Landmark Conclusion: No statistically significant difference in 5-, 10-, or 12-year all-cause or melanoma-specific mortality between plaque brachytherapy and enucleation (5-year survival ~81-82% in both cohorts). This landmark trial validated eye-preserving plaque radiotherapy as the international standard of care.

The Large Tumour Trial (Pre-Enucleation Radiation):

Randomized patients with large choroidal melanoma to enucleation alone versus external beam radiation therapy (20 Gy) prior to enucleation.

Conclusion: Pre-enucleation radiation conferred no survival benefit , establishing standard enucleation alone as the definitive surgical therapy for large intraocular tumors.

Molecular and Cytogenetic Prognostication

GNAQ/GNA11 pathway mutations are common initiating drivers; monosomy 3, 8q changes, BAP1 loss and gene-expression profiles provide prognostic information. These are different roles. Prognosis also depends on stage, tumour size and other molecular findings; neither disomy 3 nor a class label guarantees a fixed risk. Consider PRAME and contemporary validated panels in specialist counselling.

Somatic BAP1 loss does not establish a germline BAP1 tumour-predisposition syndrome. Family/personal history and appropriate germline testing guide that assessment. Coordinate liver and systemic surveillance according to risk and oncology policy. Tebentafusp is an option for appropriate HLA-A*02:01-positive adults with unresectable/metastatic uveal melanoma; treatment eligibility is not determined by tumour pigmentation.

Retinoblastoma (RB)

Retinoblastoma is the most common primary malignant intraocular neoplasm of infancy and childhood, affecting approximately 1 in 15,000 to 18,000 live births . Arising from developing neuroectodermal retinal cells (cone precursor origin), 95% of cases are diagnosed before the age of 5 years.

Knudson's "Two-Hit" Hypothesis & Genetics

Tumorigenesis requires the functional inactivation of both alleles of the RB1 tumor suppressor gene , located on chromosome 13q14.2 . The RB1 gene encodes the retinoblastoma protein ( p R b pRb pR b ), a critical nuclear phosphoprotein that regulates the G 1 G_1 G 1 ​ to S S S cell cycle checkpoint by binding and inactivating E2F transcription factors:

Heritable Retinoblastoma (~40% of cases):

First Hit: Germline mutation present in all somatic cells (inherited from an affected parent in ~10%, or a de novo constitutional variant in many of the remaining cases, with mosaicism considered).

Second Hit: Somatic mutation occurring in a developing retinal progenitor cell.

Phenotype: Often bilateral or multifocal and earlier in onset; a confirmed constitutional heterozygous RB1 variant has a 50% transmission probability, with phenotype and penetrance considered in counselling.

Second Primary Cancers: Survivors harbor an exceptionally high lifetime risk of second non-ocular malignant neoplasms (principally osteosarcoma , soft tissue sarcomas, and cutaneous melanoma). External beam radiation therapy markedly compounds this risk and is now avoided.

Trilateral Retinoblastoma: An intracranial midline embryonal tumour associated with heritable retinoblastoma, which can accompany unilateral or bilateral ocular disease, most commonly a pineoblastoma (or suprasellar primitive neuroectodermal tumor).

Non-Heritable Retinoblastoma (~60% of cases):

Both mutational "hits" occur somatically within a single developing retinal cell.

Phenotype: Usually unilateral; clinical appearance alone cannot establish non-heritable status. Genetic testing and counselling clarify the risk; no family history; very low transmission risk when absence of a germline variant is confirmed; no predisposition to second non-ocular cancers.

Clinical Presentation & Staging

Leukocoria (60%): A white pupillary reflex ( "amaurotic cat's eye" ) is the most frequent presenting sign, caused by light reflection off the white, elevated intraocular tumor mass.

Strabismus (20%): Second most common presentation; sensory esotropia or exotropia resulting from macular involvement by the tumor.

Secondary Features: Secondary neovascular glaucoma with buphthalmos, pseudohypopyon (clumps of necrotic tumor cells floating in the anterior chamber mimicking endophthalmitis), vitreous haemorrhage, and aseptic orbital cellulitis.

Caution

Strict Diagnostic Contraindication: Fine-needle aspiration biopsy (FNAC) or diagnostic vitrectomy is ABSOLUTELY CONTRAINDICATED in suspected retinoblastoma. Penetration of the ocular wall breaches natural anatomical barriers, causing direct tumor seeding along the needle track into the orbit and systemic metastasis, transforming a curable intraocular tumor into a fatal extraocular malignancy.

Diagnostic Imaging: The Calcium Hallmark

B-Scan Ultrasonography: Highly reflective intraocular mass with prominent acoustic shadowing , representing intra-tumoural calcification (present in > 90 % >90\% > 90% of retinoblastomas).

MRI of Brain and Orbits: The imaging modality of choice. Evaluates: 1) Optic nerve invasion (enhancement of the retrobulbar optic nerve), 2) Extraocular scleral extension, and 3) The pineal gland (to assess current intracranial disease; a normal scan cannot exclude future occurrence). On MRI, retinoblastoma appears moderately hyperintense on T1-weighted images and hypointense on T2-weighted images. (Note: CT readily demonstrates calcification, but is strictly minimized in germline RB patients to avoid ionizing radiation-induced second malignancies).

International Intraocular Retinoblastoma Classification (IIRC)

Group A: Small intraretinal tumors ( ≤ 3 mm \le 3\text{ mm} ≤ 3 mm ) located > 3 mm >3\text{ mm} > 3 mm from fovea and > 1.5 mm >1.5\text{ mm} > 1.5 mm from disc; no subretinal or vitreous seeds.

Group B: Larger tumors or tumors located near fovea/disc; subretinal fluid ≤ 5 mm \le 5\text{ mm} ≤ 5 mm from tumor base; no seeding.

Group C: Discrete tumors with localized subretinal or vitreous seeds ≤ 3 mm \le 3\text{ mm} ≤ 3 mm from tumor.

Group D: Diffuse disease with massive, widespread subretinal or vitreous seeds ( > 3 mm >3\text{ mm} > 3 mm from tumor).

Group E: Very advanced intraocular disease destroying functional potential (tumor touching lens, anterior chamber involvement, neovascular glaucoma, phthisis bulbi, or opaque media).

Modern Management Paradigms

Intravenous Chemoreduction (IVC): VEC protocol ( V incristine, E toposide, C arboplatin), standardly administered for 6 cycles to reduce tumor volume, followed by focal consolidation with transpupillary thermotherapy (TTT) or cryotherapy .

Intra-Arterial Chemotherapy (IAC / Superselective Ophthalmic Artery Infusion): Microcatheterization via the femoral artery directly into the ostium of the ophthalmic artery, infusing Melphalan ( ± \pm ± topotecan or carboplatin). Has transformed the management of Groups C and D retinoblastoma, achieving high rates of globe salvage.

Intravitreal Chemotherapy: Direct injection of low-dose melphalan into the vitreous cavity for refractory vitreous seeding, performed with strict safety precautions (cryotherapy to injection site, hypotensive globe, avoid anterior chamber contamination).

Enucleation is often appropriate for advanced poorly seeing eyes, but decisions consider bilateral disease, spread risk and available salvage. Suspected extraocular/retrobulbar extension requires multidisciplinary staging and treatment planning. Obtain an adequate safe optic-nerve margin for histology; no fixed stump length guarantees clearance.